Association between orofacial granulomatosis and Crohn’s disease in children: Systematic review

Table 5 Treatments of children with orofacial granulomatosis n (%)

Treatment characteristics	Value(n = 104)1
A treatment was prescribed2
Yes	89 (96.7)
No	3 (3.2)
Unspecified	12 (11.5)
Number of treatment attempts reported2
One	38 (55.8)
Two	18 (26.4)
Three or more	12 (17.6)
Unspecified	21 (23.5)
More than one drug in the same treatment attempt2
Yes	36 (53.7)
No	31 (46.2)
Unspecified	22 (24.7)
Type of treatments prescribed2
Antibiotics	26 (29.2)
Anti-histaminic	10 (11.2)
Steroids-total	63 (70.8)
Topical	27 (30.3)
Intralesional	24 (27.0)
Oral	39 (43.8)
Other immunosuppressive-total	38 (42.7)
Azathioprine/6MP	11 (12.3)
Thalidomide	9 (10.1)
Infliximab	8 (9.0)
Dapsone	4 (4.5)
Tacrolimus (topic)	4 (4.5)
Methotrexate	3 (3.4)
Tacrolimus (systemic)	3 (3.4)
Hydroxychloroquine/chloroquine	2 (2.2)
Colchicine	2 (2.2)
Other treatments
5ASA	13 (14.6)
Chlorhexidine (topic)	4 (4.5)
Enteral nutrition	2 (2.2)
Fumaric acid esterase	1 (1.1)
Surgery	8 (9.0)

¹All cases that provided a detail description of clinical signs are reported in the table;

²Percentages are calculated on the number of children for which the treatment was specified. 5-AZA: 5-aminosalicylic acid.